<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2026-3310</article-id><article-id custom-type="edn" pub-id-type="custom">UJAFUX</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3310</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Stratification of the risk of thromboembolic complications according to CHA2DS2-VASc and CHA2DS2-VA scores in patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants</article-title><trans-title-group xml:lang="ru"><trans-title>Стратификация риска тромбоэмболических осложнений по шкалам CHA2DS2-VASc и CHA2DS2-VA у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты, не являющиеся антагонистами витамина K</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2013-2647</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хоанг</surname><given-names>Чыонг Хюй</given-names></name><name name-style="western" xml:lang="en"><surname>Hoang</surname><given-names>Truong Huy</given-names></name></name-alternatives><bio xml:lang="ru"><p>ул. Зыонг Куанг Чунг, д. 2, квартал Хоа Хынг, Хошимин </p><p>ул. Нгуен Лыонг Банг, д. 4, квартал Тан Ми</p></bio><bio xml:lang="en"><p>2 Duong Quang Trung Street, Hoa Hung Ward, Ho Chi Minh City </p><p>4 Nguyen Luong Bang Street, Tan My Ward, Ho Chi Minh Cit</p></bio><email xlink:type="simple">truonghh@pnt.edu.vn</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-6651-9990</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ле</surname><given-names>Тач Хай</given-names></name><name name-style="western" xml:lang="en"><surname>Le</surname><given-names>Thach Hai</given-names></name></name-alternatives><bio xml:lang="ru"><p>ул. Су Ван Хань, д. 527, квартал Хоа Хынг, Хошимин </p></bio><bio xml:lang="en"><p>527 Su Van Hanh Street, Hoa Hung Ward, Ho Chi Minh City </p></bio><email xlink:type="simple">lehaithach02@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-3586-8454</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ле</surname><given-names>Тань Конг</given-names></name><name name-style="western" xml:lang="en"><surname>Le</surname><given-names>Tan Cong</given-names></name></name-alternatives><bio xml:lang="ru"><p>ул. Зыонг Куанг Чунг, д. 2, квартал Хоа Хынг, Хошимин </p></bio><bio xml:lang="en"><p>2 Duong Quang Trung Street, Hoa Hung Ward, Ho Chi Minh City </p></bio><email xlink:type="simple">lecongtan1708@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский университет Фам Нгок Тач ; Кардиологическая больница Там Дык</institution><country>Вьетнам</country></aff><aff xml:lang="en"><institution>Pham Ngoc Thach University of Medicine ; Tam Duc Heart Hospital</institution><country>Viet Nam</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Народная больница № 115</institution><country>Вьетнам</country></aff><aff xml:lang="en"><institution>People’s Hospital 115</institution><country>Viet Nam</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Медицинский университет Фам Нгок Тач</institution><country>Вьетнам</country></aff><aff xml:lang="en"><institution>Pham Ngoc Thach University of Medicine</institution><country>Viet Nam</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>17</day><month>06</month><year>2026</year></pub-date><volume>22</volume><issue>2</issue><fpage>120</fpage><lpage>127</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Hoang T.H., Le T.H., Le T.C., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Хоанг Ч., Ле Т., Ле Т.</copyright-holder><copyright-holder xml:lang="en">Hoang T.H., Le T.H., Le T.C.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3310">https://www.rpcardio.online/jour/article/view/3310</self-uri><abstract><sec><title>Aim</title><p>Aim. To compare the performance of the CHA2DS2-VASc and the simplified CHA2DS2-VA scores in predicting 1-year thromboembolic events among patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs).</p></sec><sec><title>Material and methods</title><p>Material and methods. In this single-centre observational cohort study, we followed 212 consecutive patients (median age 76 years, 53.5% female) with non-valvular AF receiving NOAC therapy for 12 months. Baseline clinical characteristics and thromboembolic risk scores were recorded. The primary outcome was thromboembolic events, defined as a composite of ischemic stroke, transient ischemic attack, or systemic embolism. Discriminative performance of the CHA2DS2-VASc and CHA2DS2- VA scores was assessed using receiver operating characteristic analysis and compared with the DeLong test. Cox proportional hazards regression was used to identify predictors of thromboembolic events.</p></sec><sec><title>Results</title><p>Results. During follow-up, 33 patients (15.6%) experienced thromboembolic events. The median CHA2DS2-VASc score was 5 (IQR 4-6) and the median CHA2DS2- VA score was 4 (IQR 3-5). Event rates increased progressively across higher strata of both scores. The area under the receiver operating characteristic curve was 0.640 for CHA2DS2-VASc and 0.637 for CHA2DS2-VA, with no significant difference between the two scores (p=0.966). Using a cut-off value of ≥4, CHA2DS2-VASc yielded a sensitivity of 93.9% and specificity of 24.6%, while CHA2DS2-VA yielded a sensitivity of 90.9% and specificity of 30.2%. In multivariable analysis including individual score components, impaired renal function (estimated glomerular filtration rate &lt;60 mL/min/1.73 m²) was the only independent predictor of thromboembolic events (hazard ratio 2.36, 95% confidence interval 1.11-5.02; p=0.026).</p></sec><sec><title>Conclusion</title><p>Conclusion. In anticoagulated patients with AF, the CHA2DS2-VASc and CHA2DS2-VA scores demonstrated modest and comparable discrimination for 1-year thromboembolic events. A higher score threshold (≥4) identified patients with increased residual risk, while impaired renal function was the only independent predictor of events.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Сравнить прогностическую эффективность шкал CHA2DS2-VASc и упрощённой шкалы CHA2DS2-VA в прогнозировании тромбоэмболических событий в течение 1 года у пациентов с фибрилляцией предсердий (ФП), получающих прямые оральные антикоагулянты (ПОАК), не являющиеся антагонистами витамина K.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В одноцентровое наблюдательное когортное исследование в течение 12 мес. последовательно включены 212 пациентов (медиана возраста 76 лет, 53,5% женщин) с неклапанной ФП, получавших терапию ПОАК. Были зарегистрированы исходные клинические характеристики и показатели тромбоэмболического риска. Первичной конечной точкой являлись тромбоэмболические события, определяемые как комбинированный показатель, включавший ишемический инсульт, транзиторную ишемическую атаку или системную эмболию. Дискриминационная способность шкал CHA2DS2-VASc и CHA2DS2-VA оценивалась с помощью анализа ROC-кривых с последующим сравнением по тесту Делонга. Для выявления предикторов тромбоэмболических событий применялась регрессия пропорциональных рисков Кокса.</p></sec><sec><title>Результаты</title><p>Результаты. В течение периода наблюдения у 33 пациентов (15,6%) были зарегистрированы тромбоэмболические события. Медиана баллов по шкале CHA2DS2-VASc составила 5 (межквартильный размах (МКР) 4-6), по шкале CHA2DS2-VA – 4 (МКР 3-5). Частота событий последовательно возрастала с увеличением значений обеих шкал. Площадь под ROC-кривой составила 0,640 для CHA2DS2-VASc и 0,637 для CHA2DS2-VA, без статистически значимых различий между шкалами (p=0,966). При пороговом значении ≥4 шкала CHA2DS2-VASc характеризовалась чувствительностью 93,9% и специфичностью 24,6%, тогда как для CHA2DS2-VA чувствительность составила 90,9%, а специфичность – 30,2%. При многофакторном анализе с включением отдельных компонентов шкал нарушение функции почек (расчётная скорость клубочковой фильтрации &lt;60 мл/мин/1,73 м²) оказалось единственным независимым предиктором тромбоэмболических событий (отношение рисков 2,36; 95% доверительный интервал 1,11-5,02; p=0,026).</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с ФП, получающих ПОАК, шкалы CHA2DS2-VASc и CHA2DS2-VA продемонстрировали умеренную и сопоставимую дискриминационную способность в прогнозировании тромбоэмболических событий в течение 1 года. Более высокий порог шкалы (≥4) позволил выявить пациентов с повышенным остаточным риском, тогда как нарушение функции почек являлось единственным независимым предиктором неблагоприятных событий.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>CHA2DS2-VA</kwd><kwd>CHA2DS2-VASc</kwd><kwd>пероральная антикоагулянтная терапия</kwd><kwd>тромбоэмболические осложнения</kwd><kwd>фибрилляция предсердий</kwd><kwd>ПОАК</kwd><kwd>ишемический инсульт</kwd><kwd>нарушение функции почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>CHA2DS2-VA</kwd><kwd>CHA2DS2-VASc</kwd><kwd>oral anticoagulant therapy</kwd><kwd>thromboemboliс complications</kwd><kwd>atrial fibrillation</kwd><kwd>NOACs</kwd><kwd>ischemic stroke</kwd><kwd>renal dysfunction</kwd></kwd-group><funding-group><funding-statement xml:lang="en">We sincerely thank the administrative and medical staff of People’s Hospital 115 and the Department of Internal Medicine, Faculty of Medicine at Pham Ngoc Thach University of Medicine for their invaluable support and assistance throughout this study.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126(10):e143-6. DOI:10.1161/CIRCULATIONAHA.112.129759.</mixed-citation><mixed-citation xml:lang="en">McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126(10):e143–e146. doi:10.1161/CIRCULATIONAHA.112.129759</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Van Gelder IC, Kotecha D, Rienstra M, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-414. DOI:10.1093/eurheartj/ehae176. Erratum in: Eur Heart J. 2025;46(41):4349. DOI:10.1093/eurheartj/ehaf306.</mixed-citation><mixed-citation xml:lang="en">Van Gelder IC, Kotecha D, Rienstra M, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Boriani G, Vitolo M, Mei DA. CHA2DS2-VA instead of CHA2DS2-VASc for stroke risk stratification in patients with atrial fibrillation: not just a matter of sex. Europace. 2024;26(11):euae281. DOI:10.1093/europace/euae281.</mixed-citation><mixed-citation xml:lang="en">Boriani G, Vitolo M, Mei DA. CHA2DS2-VA instead of CHA2DS2-VASc for stroke risk stratification in patients with atrial fibrillation: not just a matter of sex. Europace. 2024;26(11):euae281. doi:10.1093/europace/euae281</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sullivan RM, Zhang J, Zamba G, et al. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol. 2012;110(12):1799-802. DOI:10.1016/j.amjcard.2012.08.014.</mixed-citation><mixed-citation xml:lang="en">Sullivan RM, Zhang J, Zamba G, Lip GYH, Olshansky B. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol. 2012;110(12):1799-1802. doi:10.1016/j.amjcard.2012.08.014</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wu VC, Wu M, Aboyans V, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart. 2020;106(7):534-40. DOI:10.1136/heartjnl-2019-315065.</mixed-citation><mixed-citation xml:lang="en">Wu VCC, Wu M, Aboyans V, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart. 2020;106(7):534-540. doi:10.1136/heartjnl-2019-315065</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-72. DOI:10.1378/chest.09-1584.</mixed-citation><mixed-citation xml:lang="en">Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272. doi:10.1378/chest.09-1584</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. DOI:10.1093/eurheartj/ehr488.</mixed-citation><mixed-citation xml:lang="en">Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Okumura K, Inoue H, Atarashi H, et al.; J-RHYTHM Registry Investigators. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation - An analysis of the J-RHYTHM registry. Circ J. 2014;78(7):1593-9. DOI:10.1253/circj.CJ-14-0144.</mixed-citation><mixed-citation xml:lang="en">Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation - An analysis of the J-RHYTHM registry. Circ J. 2014;78(7):1593-1599. doi:10.1253/circj.CJ-14-0144</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Med. 2009;6(1):e16. DOI:10.1371/journal.pmed.1000016.</mixed-citation><mixed-citation xml:lang="en">Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Med. 2009;6(1):e16. doi:10.1371/journal.pmed.1000016</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019;40(5):475. DOI:10.1093/eurheartj/ehy686.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. Standards of Medical Care in Diabetes – 2018 Abridged for Primary Care Providers. Clin Diabetes. 2018;36(1):14-37. DOI:10.2337/cd17-0119.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clin Diabetes. 2022;40(1):10-38. doi:10.2337/cd17-0119</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Teppo K, Lip GYH, Airaksinen KEJ, et al. Comparing CHA2DS2-VA and CHA2DS2- VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur. 2024;43:100967. DOI:10.1016/j.lanepe.2024.100967.</mixed-citation><mixed-citation xml:lang="en">Teppo K, Lip GYH, Airaksinen KEJ, et al. Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Heal – Eur. 2024;43:100967. doi:10.1016/j.lanepe.2024.100967</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KAA, Lucas JE, Pieper KS, et al.; GARFIELD-AF Investigators. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELDAF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. DOI:10.1136/bmjopen-2017-017157.</mixed-citation><mixed-citation xml:lang="en">Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. doi:10.1136/bmjopen-2017-017157</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KAA, Virdone S, Pieper KS, et al.; GARFIELD-AF Investigators. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2022;8(2):214-27. DOI:10.1093/ehjqcco/qcab028.</mixed-citation><mixed-citation xml:lang="en">Fox KAA, Virdone S, Pieper KS, et al. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. Eur Hear J - Qual Care Clin Outcomes. 2022;8(2):214-227. doi:10.1093/ehjqcco/qcab028</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lam SHM, Romiti GF, Corica B, et al. Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry. Eur Hear J Cardiovasc Pharmacother. 2025;11(5):433-40. DOI:10.1093/ehjcvp/pvaf031.</mixed-citation><mixed-citation xml:lang="en">Lam SHM, Romiti GF, Corica B, et al. Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registryv. Eur Hear J - Cardiovasc Pharmacother. 2025;11(5):433-440. doi:10.1093/ehjcvp/pvaf031</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Matusik PT, Heleniak Z, Undas A. Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues. Anatol J Cardiol. 2022;26(12):857-63. DOI:10.5152/AnatolJCardiol.2022.2426.</mixed-citation><mixed-citation xml:lang="en">Matusik PT, Heleniak Z, Undas A. Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues. Anatol J Cardiol. 2022;26(12):857-863. doi:10.5152/AnatolJCardiol.2022.2426</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chua SK, Hsieh FI, Hu CJ, et al.; Taiwan Stroke Registry Investigators. Prognostic impact of renal dysfunction on embolic stroke of undetermined source-Role beyond CHA2 DS2 -VASc score: Results from Taiwan Stroke Registry. Eur J Neurol. 2021;28(4):1253-64. DOI:10.1111/ene.14662.</mixed-citation><mixed-citation xml:lang="en">Chua S-K, Hsieh F-I, Hu C-J, et al. Prognostic impact of renal dysfunction on embolic stroke of undetermined source-Role beyond CHA2 DS2 -VASc score: Results from Taiwan Stroke Registry. Eur J Neurol. 2021;28(4):1253-1264. doi:10.1111/ene.14662</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">D’Errico MM, Piscitelli P, Mirijello A, et al. CHA2DS2-VASc and R2CHA2DS2-VASc scores predict mortality in high cardiovascular risk population. Eur J Clin Invest. 2022;52(11):e13830. DOI:10.1111/eci.13830.</mixed-citation><mixed-citation xml:lang="en">D’Errico MM, Piscitelli P, Mirijello A, et al. CHA2DS2-VASc and R2CHA2DS2-VASc scores predict mortality in high cardiovascular risk population. Eur J Clin Invest. 2022;52(11):e13830. doi:10.1111/eci.13830</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hoang TH, Le TH, Le TC. Direct oral anticoagulants in very elderly patients with atrial fibrillation: one-year outcomes. Arch Balk Med Union. 2025;60(4):465-74. DOI:10.31688/ABMU.2025.60.4.02.</mixed-citation><mixed-citation xml:lang="en">Hoang TH, Le TH, Le TC. Direct oral anticoagulants in very elderly patients with atrial fibrillation: one-year outcomes. Arch Balk Med Union. 2025;60(4):465-474. doi:https://doi.org/10.31688/ABMU.2025.60.4.02</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hijazi Z, Lindbäck J, Alexander JH, et al.; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582-90. DOI:10.1093/eurheartj/ehw054.</mixed-citation><mixed-citation xml:lang="en">Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582-1590. doi:10.1093/eurheartj/ehw054</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
